Fibrinogen gamma chain (FGG) antibodies are immunological tools targeting the gamma subunit of fibrinogen, a critical plasma glycoprotein involved in blood coagulation and wound healing. Fibrinogen consists of three pairs of polypeptide chains (α, β, γ) that polymerize to form fibrin clots during hemostasis. The gamma chain (FGG) plays a key role in fibrin cross-linking and interactions with platelets, thrombin, and other clotting factors.
FGG antibodies are widely utilized in research to study fibrinogen structure, function, and dysregulation in diseases. They help detect FGG expression in immunoassays (e.g., Western blot, ELISA, immunohistochemistry) and investigate fibrinogen-related pathologies, such as thrombosis, bleeding disorders, and liver diseases where fibrinogen synthesis is impaired. Additionally, FGG autoantibodies have been implicated in rare autoimmune conditions, such as acquired hypofibrinogenemia, where they accelerate fibrinogen clearance.
In cancer research, FGG antibodies explore fibrinogen’s role in tumor progression, as fibrinogen fragments promote angiogenesis and metastasis. Studies also examine genetic FGG variants linked to thrombotic risks. Beyond diagnostics, these antibodies aid in developing therapeutic strategies, such as antithrombotic drugs targeting fibrinogen pathways. Their specificity makes them valuable for both basic science and clinical applications, bridging insights into coagulation biology and disease mechanisms.